Ovarian Cancer
9
Companies
11
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Johnson & Johnson
Trabectedin
AstraZeneca PLC
Saruparib (AZD5305)
Cellectar Biosciences, Inc.
NOV-002
Seagen Inc.
tisotumab vedotin
CASI Pharmaceuticals, Inc.
Panzem Nanocrystal Colloidal Dispersion (NCD)
CASI Pharmaceuticals, Inc.
MKC-1
Zentalis Pharmaceuticals, Inc.
Niraparib
Incyte Corporation
INCB123667
Xencor, Inc.
vudalimab
CASI Pharmaceuticals, Inc.
ENMD-2076
Eli Lilly and Company
Prexasertib
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Trabectedin | Phase 3 | — | — | — |
| AZN AstraZeneca PLC | Saruparib (AZD5305) | Phase 3 | — | — | — |
| CLRB Cellectar Biosciences, Inc. | NOV-002 | Phase 2 | — | — | — |
| SGEN Seagen Inc. | tisotumab vedotin | Phase 2 | — | — | — |
| CASI CASI Pharmaceuticals, Inc. | Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | — | — | — |
| CASI CASI Pharmaceuticals, Inc. | MKC-1 | Phase 2 | — | — | — |
| ZNTL Zentalis Pharmaceuticals, Inc. | Niraparib | Phase 2 | — | — | — |
| INCY Incyte Corporation | INCB123667 | Phase 2 | — | — | — |
| XNCR Xencor, Inc. | vudalimab | Phase 2 | — | — | — |
| CASI CASI Pharmaceuticals, Inc. | ENMD-2076 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | Prexasertib | Phase 2 | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.